

General Assembly

Raised Bill No. 5201

February Session, 2004

LCO No. 1014

* HB05201APP 041404 *

Referred to Committee on Insurance and Real Estate

Introduced by: (INS)

AN ACT CONCERNING NEWBORN SCREENING AND MEDICALLY NECESSARY NUTRITIONAL FORMULA FOR CYSTIC FIBROSIS.

Be it enacted by the Senate and House of Representatives in General Assembly convened:

- 1 Section 1. Section 38a-492c of the general statutes is repealed and the
- 2 following is substituted in lieu thereof (*Effective October 1, 2004*):
- 3 (a) For purposes of this section:
- 4 (1) "Inherited metabolic disease" means a disease for which
- 5 newborn screening is required under section 19a-55, as amended by
- 6 this act.
- 7 (2) "Low protein modified food product" means a product
- 8 formulated to have less than one gram of protein per serving and
- 9 intended for the dietary treatment of an inherited metabolic disease
- 10 under the direction of a physician.
- 11 (3) "Amino acid modified preparation" means a product intended
- 12 for the dietary treatment of an inherited metabolic disease under the
- 13 direction of a physician.

- (4) "Specialized formula" means a nutritional formula for children up to age three that is exempt from the general requirements for nutritional labeling under the statutory and regulatory guidelines of the federal Food and Drug Administration and is intended for use solely under medical supervision in the dietary management of specific diseases.
 - (b) Each individual health insurance policy providing coverage of the type specified in subdivisions (1), (2), (4), (6), (11) and (12) of section 38a-469 delivered, issued for delivery or renewed in this state on or after October 1, 1997, shall provide coverage for amino acid modified preparations and low protein modified food products for the treatment of inherited metabolic diseases if the amino acid modified preparations or low protein modified food products are prescribed for the therapeutic treatment of inherited metabolic diseases and are administered under the direction of a physician.
 - (c) Each individual health insurance policy providing coverage of the type specified in subdivisions (1), (2), (4), (6), (11) and (12) of section 38a-469 delivered, issued for delivery or renewed in this state on or after October 1, 2001, shall provide coverage for specialized formulas when such specialized formulas are medically necessary for the treatment of a disease or condition and are administered under the direction of a physician.
- (d) Such policy shall provide coverage for such food products andformulas on the same basis as outpatient prescription drugs.
- Sec. 2. Section 38a-518c of the general statutes is repealed and the following is substituted in lieu thereof (*Effective October 1, 2004*):
- 40 (a) For purposes of this section:
- 41 (1) "Inherited metabolic disease" means a disease for which 42 newborn screening is required under section 19a-55, as amended by 43 <u>this act</u>.

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

- 44 (2) "Low protein modified food product" means a product 45 formulated to have less than one gram of protein per serving and 46 intended for the dietary treatment of an inherited metabolic disease 47 under the direction of a physician.
 - (3) "Amino acid modified preparation" means a product intended for the dietary treatment of an inherited metabolic disease under the direction of a physician.
 - (4) "Specialized formula" means a nutritional formula for children up to age three that is exempt from the general requirements for nutritional labeling under the statutory and regulatory guidelines of the federal Food and Drug Administration and is intended for use solely under medical supervision in the dietary management of specific diseases.
 - (b) Each group health insurance policy providing coverage of the type specified in subdivisions (1), (2), (4), (6), (11) and (12) of section 38a-469 delivered, issued for delivery or renewed in this state on or after October 1, 1997, shall provide coverage for amino acid modified preparations and low protein modified food products for the treatment of inherited metabolic diseases if the amino acid modified preparations or low protein modified food products are prescribed for the therapeutic treatment of inherited metabolic diseases and are administered under the direction of a physician.
 - (c) Each group health insurance policy providing coverage of the type specified in subdivisions (1), (2), (4), (6), (11) and (12) of section 38a-469 delivered, issued for delivery or renewed in this state on or after October 1, 2001, shall provide coverage for specialized formulas when such specialized formulas are medically necessary for the treatment of a disease or condition and are administered under the direction of a physician.
- 73 (d) Such policy shall provide coverage for such food products and 74 formulas on the same basis as outpatient prescription drugs.

Sec. 3. Section 19a-55 of the general statutes, as amended by section 5 of public act 03-3 of the June 30 special session, is repealed and the following is substituted in lieu thereof (*Effective October 1, 2004*):

- (a) The administrative officer or other person in charge of each institution caring for newborn infants shall cause to have administered to every such infant in its care an HIV-related test, as defined in section 19a-581, a test for phenylketonuria and other metabolic diseases, cystic fibrosis, hypothyroidism, galactosemia, sickle cell disease, maple syrup urine disease, homocystinuria, biotinidase deficiency, congenital adrenal hyperplasia and such other tests for inborn errors of metabolism as shall be prescribed by the Department of Public Health. The tests shall be administered as soon after birth as is medically appropriate. If the mother has had an HIV-related test pursuant to section 19a-90 or 19a-593, the person responsible for testing under this section may omit an HIV-related test. The Commissioner of Public Health shall (1) administer the newborn screening program, (2) direct persons identified through the screening program to appropriate specialty centers for treatments, consistent with any applicable confidentiality requirements, and (3) set the fees to be charged to institutions to cover all expenses of the comprehensive screening program including testing, tracking and treatment. The fees to be charged pursuant to subdivision (3) of this section shall be set at a minimum of twenty-eight dollars. The commissioner shall adopt regulations, in accordance with chapter 54, specifying the abnormal conditions to be tested for and the manner of recording and reporting results. On or before January 1, 2004, such regulations shall include requirements for testing for amino acid disorders, organic acid disorders and fatty acid oxidation disorders, including, but not limited to, long-chain 3-hydroxyacyl CoA dehydrogenase (L-CHAD) and medium-chain acyl-CoA dehydrogenase (MCAD).
- (b) The provisions of this section shall not apply to any infant whose parents object to the test or treatment as being in conflict with their religious tenets and practice.

75

76

77

78

79

80

81

82

83

8485

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

This act shall take effect as follows:	
Section 1	October 1, 2004
Sec. 2	October 1, 2004
Sec. 3	October 1, 2004

INS Joint Favorable

PH Joint Favorable

APP Joint Favorable